the aid library

LIST OPTIONS

Filter

1182

Sort by:

Direction:

Download (577)

View PDF (2939)

Guidelines - European AIDS Clinical Society (EACS)

European AIDS Clinical Society (EACS) European AIDS Clinical Society (EACS) (2020) C2

Version 10.1_5 October 2020 These Guidelines are available in different formats: As a paper booklet, a PDF, a mobile app, and now also as a website. The 2019 version of the Guidelines introduces a new drug-drug interaction panel and now consists of six main sections, including a general overview ... more

Download (334)

View PDF (317)

WHO Methodology for Point Prevalence Survey on Antibiotic Use in Hospitals

World Health Organization WHO (2019) C_WHO

Version 1.1. The WHO protocol has been adapted to resource-limited settings and builds on existing methodologies from the European Centre for Disease Prevention and Control (ECDC), the Global PPS project from University of Antwerp, the US Centers for Disease Control and Prevention (CDC), and the Med... more

Download (649)

View PDF (756)

Water, Sanitation and Hygiene (WASH) in Schools

World Health Organization (WHO) (2012) C_WHO

A companion to the Child Friendly Schools Manual
WASH in Schools aims to improve the health and learning performance of school-aged children – and, by extension, that of their families – by reducing the incidence of water and sanitation-related diseases. Every child friendly school r... more

Download (1143)

View PDF (1304)

Medicinal products under development for the treatment of Ebola

European Medicines Agency EMA (2014)

Interim Assessement Report The EMA review was started by the Agency’s Committee for Medicinal Products for Human Use (CHMP) to support decision-making by health authorities. This first interim report includes information on seven experimental medicines intended for the treatment of people infecte... more

Download (86)

View PDF (104)

British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2015(2016 interim update)

British HIV Association (2016) CC

The guidelines are aimed at clinical professionals directly involved with and responsible for the care of adults with HIV infection, and at community advocates responsible for promoting the best interests and care of HIV-positive adults. They should be read in conjunction with other published BHIVA ... more

Download (266)

View PDF (580)

Latent Tuberculosis Infection : Updated and consolidated guidelines for programmatic management
recommended

World Health Organization WHO (2018) C_WHO

The consolidated guidelines are expected to provide the basis and rationale for the development of national guidelines for LTBI management, adapted to the national and local epidemiology of TB, the availability of resources, the health infrastructure and other national and local determinants. The gu... more

Download (1040)

View PDF (620)

Medicinal Plants in Papua New Guinea

World Health Organization (WHO), Regional Office for the Western Pacific (2009) C_WHO

Traditional medicine, including the knowledge, skills and practices of holistic health care, exists in all cultures. It is based on indigenous theories, beliefs and experiences and is widely accepted for its role in health maintenance and the treatment of disease.Medicinal plants are the main ingred... more

Download (49)

View PDF (583)

Q&A: Antibiotic resistance: where does it come from and what can we do about it?

Wright G.D. BMC Biology (2010) C2

Historically, the discovery of the sulfa drugs in the 1930s and the subsequent development of penicillin during World War II ushered in a new era in the treatment of infectious diseases. Infections that were common causes of death and disease in the pre-... more

Download (202)

View PDF (239)

Managing People with Hypertension and Cardiovascular Disease during COVID-19: Considerations for Health Providers, 3 June 2020

Pan American Health Organisation PAHO (2020) C_WHO

Primary care health centers and providers who care for individuals with hypertension and cardiovascular disease have an important role to play in ensuring continued access to care, reducing the risk of coronavirus infection, and appropriately managing people with these co-morbidities who acquire COV... more

Download (118)

View PDF (162)

Guidelines for Diagnosing and Managing Disseminated Histoplasmosis among People Living with HIV
recommended

World Health Organization WHO (2020) C_WHO

Histoplasmosis is a disease caused by the fungus Histoplasma capsulatum. This disease is highly endemic in some regions of North America, Central America, and South America and is also reported in certain countries of Asia and Africa. It often affects people with impaired immunity, including people ... more

Download (56)

View PDF (80)

Dietary salt intake survey in the Republic of Moldova, 2016

World Health OrganizationEurope (2018) C_WHO

High salt consumption is an important determinant of high blood pressure and reducing it would improve health outcomes by lowering cardiovascular disease and therefore death rates. Reducing salt intake has been identified as one of the most effective public health measures and is one of the leading ... more

Download (62)

View PDF (90)

Expanding our understanding of post COVID-19 condition: report of a WHO webinar

World Health Organization WHO (2021) C_WHO

On 9 February 2021, a first webinar entitled “Expanding our understanding of Post COVID-19 condition” was held under the auspices of WHO and in consultation with the International Severe Acute Respiratory and Emerging Infection Consortium(ISARIC), Global Research Collaboration for Infectious Dis... more

Download (57)

View PDF (116)

Economic Evaluation of Community Based Practitioners In Low-And Middle-Income Countries - A literature review, country case studies and a generalized cost-effectiveness model

global health workforce alliance World Health Organization (2015) C_WHO

Community-based strategies play a significant role in many health systems in low- and middle-income countries, especially in light of critical shortages in the health workforce. The term community health worker has been used to refer to volunteers and salaried, professional or lay health workers wit... more

Download (79)

View PDF (130)

Preventing disease through healthy environments: a global assessment of the burden of disease from environmental risks

Prüss-Ustün, A.; J. Wolf, C. Corvalán, et al. World Health Organization WHO (2018) C_WHO

The main message emerging from this new comprehensive global assessment is that premature death and disease can be prevented through healthier environments – and to a significant degree. Analysing the latest data on the environment-disease nexus and the devastating impact of environmental hazards ... more

Download (89)

View PDF (152)

National Guidelines for the Management of Viral Hepatitis

Spearman, CWN; MW Sonderup, Y Pillay et al. National Department of Health South Africa (2020) CC

Viral hepatitis is defined as inflammation of the liver cells due to viral infection. The burden of liver disease in South Africa is mostly underestimated as viral hepatitis, in particular chronic infection, is a silent and neglected cause of morbidity and mortality. However, the burden of disease i... more

Download (75)

View PDF (97)

De l’intention a l’action : le pouvoir des individus. Perspectives de personnes avec une expérience vécue de maladie nontransmissible, de trouble de la santé mentale et de maladie neurologique

World Health Organisation (WHO) (2023) C_WHO

Il s’agit du premier rapport d’une collection de l’OMS intitulée De l’intention à l’action, qui vise à renforcer la base de données probantes sur l’impact de la participation significative et à combler le manque d’approches normalisées pour permettre la participation significativ... more

Download (143)

View PDF (137)

Dementia in Latin America and the Caribbean: Prevalence, Incidence, Impact, and Trends over Time

World Health Organisation (WHO) (2023) C_WHO

The chapter Dementia in Latin America and the Caribbean: Prevalence, Incidence, Impact, and Trends over Time, is part of the publication series titled “Decade of Healthy Aging: situation and challenges”. This document aims to provide an outline of the current situation in Latin America and the C... more

Download (115)

View PDF (106)

Clinical Management of Yellow Fever in the Region of the Americas. Experiences and Recommendations for Health Services

Pan American Health Organisation PAHO (2023) CC

The waves of yellow fever transmission in the Region of the Americas in 2016–2018 involved the largest number of human and epizootic cases to be reported in several decades. Yellow fever is a serious viral hemorrhagic disease that poses a challenge for health professionals. It requires early recog... more

Download (154)

View PDF (130)

Global report on hypertension: the race against a silent killer
recommended

World Health Organisation (WHO) (2023) C_WHO

This report compiles data for the first time on the far-reaching consequences of uncontrolled hypertension, including heart attacks, strokes and premature death, along with substantial economic losses for communities and countries. It also contains information on the global, regional and country-lev... more

Download (176)

View PDF (247)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Latent Tuberculosis Infection : Updated and consolidated guidelines for programmatic management recommended

Guidelines for Diagnosing and Managing Disseminated Histoplasmosis among People Living with HIV recommended

Global report on hypertension: the race against a silent killer recommended

Latent Tuberculosis Infection : Updated and consolidated guidelines for programmatic management
recommended

Guidelines for Diagnosing and Managing Disseminated Histoplasmosis among People Living with HIV
recommended

Global report on hypertension: the race against a silent killer
recommended